← Leaderboards
Alejandro Benjamin Balazs
Massachusetts General Hospital
$9,513,558
Attributed
$9,513,558
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,513,558 · 7
By mechanism
R01$3,217,539 · 2
DP2$2,610,000 · 1
DP1$2,104,200 · 1
P30$1,317,427 · 2
K22$264,392 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Todd M Allen$28,600,717
- Simon C Robson$16,000,011
- Andrew M Tager$6,891,119
- David T Scadden$62,181,067
- Galit Alter$32,273,423
Others in their field
Top investigators on “Doctor Of Philosophy”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Sharon A Nachman · Johns Hopkins University$116,441,543
- J Brooks Jackson · Social And Scientific Systems, Inc.$112,239,639
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,218,842
Research focus
Doctor Of PhilosophyIn VivoImmune SystemAntibodiesHiv InfectionsGrantFutureCellsInfectionImmune ResponseAnimal ModelImmuneMediatingHumanized MouseProfessorImmunityGene TransferExperimental StudyVectorEngineeringAnimalsUnited States National Institutes Of HealthMouse ModelNonhuman Primate
Grant awards (14)
Polyclonal Bi-Specific Vectored ImmunoTherapy to Functionally Cure HIV Infection$1,052,100
DP1 · FY2025 · DA · contact PI
Eliminating the Immunogenicity of AAV Vectored HIV Antibody Delivery$817,309
R01 · FY2025 · AI · contact PI
Polyclonal Bi-Specific Vectored ImmunoTherapy to Functionally Cure HIV Infection$1,052,100
DP1 · FY2024 · DA · contact PI
Eliminating the Immunogenicity of AAV Vectored HIV Antibody Delivery$822,056
R01 · FY2024 · AI · contact PI
AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIV$781,279
R01 · FY2024 · AI · contact PI
AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIV$796,895
R01 · FY2023 · AI · contact PI
Human Immune System Mouse Core$539,585
P30 · FY2023 · AI · contact PI
Human Immune System Mouse Core$153,326
P30 · FY2022 · AI · contact PI
Human Immune System Mouse Core$168,136
P30 · FY2021 · AI · contact PI
Human Immune System Mouse Core$256,295
P30 · FY2020 · AI · contact PI
Human Immune System Mouse Core$200,085
P30 · FY2019 · AI · contact PI
Engineering Humoral Immunity to Functionally Cure HIV Infection$2,610,000
DP2 · FY2015 · DA · contact PI
Development of Vectored ImmunoProphylaxis as a strategy against HIV$107,760
K22 · FY2015 · AI · contact PI
Development of Vectored ImmunoProphylaxis as a strategy against HIV$156,632
K22 · FY2014 · AI · contact PI